HBM Holdings Ltd. (HK:2142) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
HBM Holdings Ltd. has announced a collaboration between its subsidiary, Nona Biosciences, and Candid Therapeutics to develop next-generation T-cell engagers for autoimmune diseases. This partnership could result in Nona Biosciences receiving up to $320 million in payments, highlighting a significant investment in innovative healthcare solutions. The collaboration aims to leverage T-cell engagers for effective B-cell depletion, offering potential advancements in autoimmune disease treatment.
For further insights into HK:2142 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Tesla Stock Upgraded to Buy by Mizuho with a New Street-High Price Target
- 3 Penny Stocks to Watch Now, 12/17/24
- TikTok Urges U.S. Supreme Court to Halt the Ban While Meta and Google Relish
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
